Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.76 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | RGS12 | O14924 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1959337 | 0.86 | MTNR1A (1.00) | KMT2AL3MBTL1MTNR1AMTNR1BCYP3A4 | |
| SCHEMBL8578072 | 0.86 | KMT2A (0.76) | KMT2AL3MBTL1MTNR1AMTNR1BCYP3A4 | |
| SCHEMBL8579628 | 0.86 | KMT2A (0.76) | KMT2AL3MBTL1MTNR1AMTNR1BCYP3A4 | |
| SCHEMBL1032784 | 0.83 | HPGD (1.00) | KMT2AL3MBTL1MTNR1AMTNR1BCYP3A4 | |
| SCHEMBL8581842 | 0.83 | KMT2A (0.70) | KMT2AL3MBTL1MTNR1AMTNR1BCYP3A4 | |
| SCHEMBL1943256 | 0.77 | KMT2A (0.63) | KMT2AL3MBTL1MTNR1AMTNR1BCYP3A4 | |
| SCHEMBL3193701 | 0.76 | KMT2A (0.61) | KMT2AL3MBTL1MTNR1AMTNR1BCYP3A4 | |
| SCHEMBL1946240 | 0.76 | KMT2A (0.61) | KMT2AL3MBTL1MTNR1AMTNR1BCYP3A4 | |
| SCHEMBL28562224 | 0.75 | KMT2A (0.60) | KMT2AL3MBTL1MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL6449965 | 0.75 | KMT2A (0.60) | KMT2AL3MBTL1MTNR1AMTNR1BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8324224-B2 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-1444233-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD PALO ALTO INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110130362-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7795269-B2 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100222300-A1 | A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-7741331-B2 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080318983-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080194593-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7317017-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7304070-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7105665-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-6977300-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-11-24 | — | — | US | disclosed |
| US-20050101778-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050038045-A1 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-02-17 | — | — | US | disclosed |
| US-6825349-B2 | PURINE DERIVATIVES FOR TREATMENT OF GASTROINTESTINAL DISORDERS, IMMUNOLOGICAL DISORDERS, NEUROLOGICAL DISORDERS | CV THERAPEUTICS INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030229106-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030139428-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194593-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | KMT2A 2344/4885L3MBTL1 3692/4885MTNR1A 94/4885 |
| US-20110257127-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | KMT2A 2668/4885L3MBTL1 2456/4885MTNR1A 119/4885 |
| US-20050038045-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KMT2A 2668/4885L3MBTL1 2456/4885MTNR1A 119/4885 |
| US-20050101778-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KMT2A 2260/4885L3MBTL1 3836/4885MTNR1A 111/4885 |
| US-20100222300-A1 | A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | KMT2A 2668/4885L3MBTL1 2456/4885MTNR1A 119/4885 |
| US-20030139428-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KMT2A 2479/4885L3MBTL1 2716/4885MTNR1A 107/4885 |
| US-20030229106-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KMT2A 2479/4885L3MBTL1 2716/4885MTNR1A 107/4885 |
| US-20080318983-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | KMT2A 2344/4885L3MBTL1 3692/4885MTNR1A 94/4885 |
| US-20050261316-A1 | A2B Adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KMT2A 2668/4885L3MBTL1 2456/4885MTNR1A 119/4885 |
| US-20130123280-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | KMT2A 2668/4885L3MBTL1 2456/4885MTNR1A 119/4885 |
| US-20110130362-A1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | KMT2A 2668/4885L3MBTL1 2456/4885MTNR1A 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.